Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.61 |
| ▸ | GSR | P00390 | 1/20 | 0.46 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.45 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.45 |
| ▸ | NMT1 | P30419 | 5/20 | 0.44 |
| ▸ | NMT2 | O60551 | 4/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30099702 | 0.97 | FOLH1 (0.62) | FOLH1GSRRIMKLANAALAD2NMT1 | |
| SCHEMBL30099451 | 0.95 | FOLH1 (0.62) | FOLH1GSRRIMKLANAALAD2NMT1 | |
| SCHEMBL29886785 | 0.95 | FOLH1 (0.61) | FOLH1GSRRIMKLANAALAD2NMT1 | |
| SCHEMBL31154656 | 0.95 | FOLH1 (0.57) | FOLH1GSRRIMKLANAALAD2NMT1 | |
| SCHEMBL29630778 | 0.93 | FOLH1 (0.66) | FOLH1GSRRIMKLANAALAD2DPP8 | |
| SCHEMBL31344444 | 0.93 | FOLH1 (0.69) | FOLH1GSRRIMKLANAALAD2DPP8 | |
| SCHEMBL1973946 | 0.93 | FOLH1 (0.69) | FOLH1GSRRIMKLANAALAD2DPP8 | |
| SCHEMBL30984646 | 0.93 | FOLH1 (0.69) | FOLH1GSRRIMKLANAALAD2DPP8 | |
| SCHEMBL14413853 | 0.93 | FOLH1 (0.69) | FOLH1GSRRIMKLANAALAD2DPP8 | |
| SCHEMBL30026189 | 0.93 | FOLH1 (0.69) | FOLH1GSRRIMKLANAALAD2DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116425831-A | Walnut dreg anti-colon cancer peptide and application thereof | 云南农业大学 | 2023-07-14 | — | — | CN | disclosed |
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC (CA) | 2016-09-15 | — | — | US | disclosed |
| EP-2794663-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | Angiochem Inc. (CA) | 2014-10-29 | — | — | EP | disclosed |
| CN-103665170-A | Peptide therapeutic conjugates and uses thereof | ANGIOCHEM INC | 2014-03-26 | — | — | CN | disclosed |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2011-11-24 | — | — | US | disclosed |
| WO-2010063124-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | FOLH1 144/4885GSR 3115/4885RIMKLA 2154/4885 |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | FOLH1 144/4885GSR 3115/4885RIMKLA 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.